Drug Fix: Trump’s Potential Impact On FDA User Fees, Dr. Oz’s Potential Impact On CMS

Pink Sheet reporter and editors discuss concerns that the incoming administration could try to influence the upcoming FDA user fee reauthorization (:30), as well as the changes Dr. Mehmet Oz, President-elect Donald Trump’s controversial selection of to run the US Centers for Medicare and Medicaid Services, could impose if confirmed (22:35). #pharma #business More On These Topics From The Pink Sheet Trump’s US FDA User Fee Cycle: ‘An Underappreciated Threat’: https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/trumps-us-fda-user-fee-cycle-an-underappreciated-threat-GVVSHUIRXBDOHDLWQXHSLC2U4A/ Medicare Price Negotiation Under CMS Chief Oz May See Early 2025 Test: https://insights.citeline.com/pink-sheet/agency-leadership/medicare-price-negotiation-under-cms-chief-oz-may-see-early-2025-test-UOROAUBSE5CWJC65XK6Q5I37SE/ CMS Administrator Nominee Oz Is ‘Communicator’ In Sync With RFK’s Healthy Living Focus: https://insights.citeline.com/pink-sheet/agency-leadership/cms-administrator-nominee-oz-is-communicator-in-sync-with-rfks-healthy-living-focus-CHOJUI4DWVCWRFQMBZXCQYAGB4/